Company Overview
Geron Corporation operates as a commercial-stage biopharmaceutical entity dedicated to the development of therapeutics products specifically for the oncology sector. Within the broader healthcare landscape, the company functions inside the biotechnology industry, a domain characterized by high innovation requirements and significant capital expenditure needs. The organization currently maintains a market capitalization of $967.22M, generates annual revenue of $183.88M, and employs a workforce of 258 individuals. These financial dimensions indicate that while the company possesses a substantial liquidity position relative to its valuation, it operates on a mid-cap scale typical for specialized biotech firms focused on advancing specific product pipelines rather than generating massive immediate volume.
Financial Health
The company reported revenue of $183.88M for the trailing twelve months, yet this income resulted in a net income loss of $83,500,000 and an EBITDA of $-51,079,000. The substantial gap between the positive revenue figure and the significant negative net income reveals a cost structure where operational expenses, likely driven by research and development or regulatory activities, heavily outweigh gross profits. Free cash flow stands at $-78,356,248, indicating that the company is currently burning cash to fund its operations and pipeline development rather than generating surplus liquidity for shareholders or dividends. Despite these outflows, the balance sheet holds $357.92M in cash against $121.99M in debt, creating a net cash position that provides a buffer for continued investment. The debt-to-equity ratio is recorded at 54.01, suggesting a leveraged capital structure common in early-stage biotechnology, though the high cash reserve mitigates immediate solvency risks. The current ratio is 4.66, which indicates a very strong short-term liquidity position where current assets significantly exceed current liabilities. Furthermore, the return on equity is -33.0% and the return on assets is -5.5%, metrics that reveal the company is currently destroying shareholder value and utilizing assets to generate losses rather than returns.
Valuation Assessment
The P/E Ratio (TTM) is listed as N/A due to the lack of net income, while the forward P/E is 18.88, a discrepancy that implies market expectations for future profitability that are not reflected in current trailing earnings. The price-to-book ratio is 4.28, indicating that the market is valuing the company at a significant premium over its tangible book value, likely reflecting the high perceived potential of its intellectual property and pipeline. Alternative valuation metrics include a price-to-sales ratio of 5.26 and an EV/EBITDA of -14.32, which suggests that traditional earnings-based multiples are less relevant, and valuation is instead driven by sales growth potential and asset backing. The stock has traded between a 52-week high of $2.01 and a 52-week low of $1.04, placing the current trading range within a volatile band that reflects the uncertainty often associated with biotechnology equities. The beta is 0.62, which means the stock price volatility is historically lower than the broader market, suggesting a defensive characteristic relative to the high-beta nature of many large-cap technology stocks.
Growth & Income
Revenue growth for the year-over-year period is 1.0%, while earnings growth is N/A due to the company's continued net losses. The absence of positive earnings growth relative to the modest revenue increase implies that the company is in an investment phase where top-line expansion does not yet translate to bottom-line profitability. As a non-dividend payer, the company maintains a dividend yield of N/A and a payout ratio of 0.0%, meaning all available earnings and cash flows are theoretically available for reinvestment into the business rather than distribution to shareholders. This reinvestment strategy is standard for biotechnology firms in the commercial stage, prioritizing the advancement of the RYTELO telomerase inhibitor pipeline and other oncology therapeutics over immediate income generation for investors.